Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
The Analyst Landscape: 27 Takes On Biogen- Benzinga | news.google.com • |
7 Retirement Stocks to Buy at a 52-Week Low in April | investorplace.com • |
Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) (NASDAQ:BIIB) | news.google.com • |
Cwm LLC Decreases Stake in Biogen Inc. (NASDAQ:BIIB) | news.google.com • |
FY2024 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Boosted by Analyst | news.google.com • |
Q3 2024 EPS Estimates for Biogen Inc. Lifted by Analyst (NASDAQ:BIIB) | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-24 | 2024-03 | 3.45 | 3.67 | 0.22 | 6.38% |
2024-02-13 | 2023-12 | 3.16 | 2.95 | -0.21 | -6.65% |
2023-11-08 | 2023-09 | 3.99 | 4.36 | 0.37 | 9.27% |
2023-07-25 | 2023-06 | 3.77 | 4.02 | 0.25 | 6.63% |
2023-04-25 | 2023-03 | 3.25 | 3.4 | 0.15 | 4.62% |
2023-02-15 | 2022-12 | 3.51 | 4.05 | 0.54 | 15.38% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-09-05 | HSBC | Upgrade | Buy | |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-08-28 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-13 | Mizuho | Upgrade | Buy | Buy |
2023-08-07 | Atlantic Equities | Upgrade | Neutral | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-15 | ALEXANDER SUSAN H | Officer | 51.68K | Conversion of Exercise of derivative security |
2023-06-25 | DORSA CAROLINE D | Director | 24.82K | Stock Award(Grant) |
2024-02-15 | GREGORY GINGER | Officer | 13.58K | Conversion of Exercise of derivative security |
2023-06-25 | HAWKINS WILLIAM A III | Director | 5.15K | Stock Award(Grant) |
2024-02-15 | IZZAR RACHID | Officer | 9.70K | Conversion of Exercise of derivative security |
2024-02-15 | KRAMER ROBIN C | Officer | 6.23K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Primecap Management Company | 16.03M | 4.56B | 11.07% |
2023-06-29 | Blackrock Inc. | 14.07M | 4.01B | 9.71% |
2023-06-29 | Vanguard Group Inc | 12.20M | 3.47B | 8.42% |
2023-06-29 | State Street Corporation | 6.89M | 1.96B | 4.75% |
2023-06-29 | Wellington Management Group, LLP | 5.35M | 1.52B | 3.69% |
2023-06-29 | JP Morgan Chase & Company | 4.47M | 1.27B | 3.09% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard/Primecap Fund | 9.00M | 2.56B | 6.21% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.56M | 1.23B | 3.15% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.51M | 1.28B | 3.11% |
2023-06-29 | Vanguard 500 Index Fund | 3.45M | 981.68M | 2.38% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 2.45M | 655.85M | 1.69% |
2023-06-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 2.18M | 621.04M | 1.51% |
Split | Date |
---|---|
3 : 1 | 2001-01-18 |
2 : 1 | 1999-12-21 |
-
Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dad and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........ -
Wow no. Hard pass $BIIB read FDA report
-
Short interest plus all time low in five years with a negative PEG. If u r betting on a deus ex machina stay in $BIIB otherwise join the shorts
-
I bought BIIIB many times. It is good price ( under 245)to buy. I am confident it will be above 270 couple month later
-
Head & shoulders pattern coming up 🥺 $BIIB
-
-
Added at end of power hour! go low bby!! Buying the rumor (sell before the news... prob another crash $BIIB) #bounceoffthebottomplz support at $225. Hope there are bulls tomorrow 🥰🥰 #stopthevotecountthevote
-
-
I love the 5 year chart $BIIB
-
I think I’m going to bail. I’m pretty much even money here. I think there are better options than this. It’s languishing to say the least. Anyone have any suggestions? NBIX?
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
$BIIB coming back down today
-
so wierd... sneaky....
-
$BIIB come on here we go
-
estimated minus -4% to -5% CLose
-
SELL SELLL..... THIS NEVER UP WILL DROP.
-
Chance to sell sell now... will drop soonly
-
Sell sell quick...
-
The Analyst Landscape: 27 Takes On Biogen- Benzinga
news.google.com • -
7 Retirement Stocks to Buy at a 52-Week Low in April
investorplace.com • -
Cwm LLC Decreases Stake in Biogen Inc. (NASDAQ:BIIB)
news.google.com • -
FY2024 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Boosted by Analyst
news.google.com • -
Q3 2024 EPS Estimates for Biogen Inc. Lifted by Analyst (NASDAQ:BIIB)
news.google.com • -
How to Take Advantage of moves in (BIIB)
news.google.com • -
Barclays Lowers Biogen (NASDAQ:BIIB) Price Target to $200.00
news.google.com • -
Q2 2024 EPS Estimates for Biogen Inc. Lifted by Analyst (NASDAQ:BIIB)
news.google.com • -
BIIB June 7th Options Begin Trading
news.google.com • -
Biogen (NASDAQ:BIIB) Rating Reiterated by Needham & Company LLC
news.google.com • -
Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
news.google.com • -
Why Biogen Stock Leaped Nearly 5% Higher Today
news.google.com • -
3-Stock Lunch: TXN, BIIB & CMG
youtube.com • -
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
news.google.com • -
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
news.google.com • -
Biogen (BIIB) Q1 2024 Earnings Call Transcript
news.google.com • -
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
news.google.com • -
BIIB Stock: Biogen Tops Q1 Estimates with Alzheimer's Boost
news.google.com • -
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
news.google.com • -
Biogen stock gains on Q1 earnings beat (NASDAQ:BIIB)
news.google.com • -
Biogen tops earnings expectations but revenue falls short
news.google.com • -
Cerity Partners LLC Increases Position in Biogen Inc. (NASDAQ:BIIB)
news.google.com • -
Should You Be Confident in Biogen (BIIB)?
news.google.com • -
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
seekingalpha.com • -
Three-Stock Lunch: Biogen, DocuSign & Gap
youtube.com • -
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
investorplace.com • -
EU medicines regulator backs Biogen's ALS drug
reuters.com • -
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
investorplace.com • -
Where Are Biotech ETFs Headed After Q4 Earnings?
zacks.com • -
Biogen's rare genetic disorder drug gets approval in EU
reuters.com • -
Wall Street Brunch: Retail Inflation In Focus
seekingalpha.com • -
7 Biotech Stocks Fighting America's Deadliest Diseases
investorplace.com • -
Biogen Ends Development of Alzheimer's Drug Aduhelm
barrons.com • -
Biogen halts development of controversial Alzheimer's drug
marketwatch.com • -
Time to Load Up on This New Magnificent 7 of ‘Strong Buy' Stocks
investorplace.com • -
2 low-priced gene therapy stocks to speculate on
marketbeat.com • -
Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness
investorplace.com • -
Top 3 Healthcare Stock Picks for the New Year
investorplace.com • -
Wells Fargo's top pharma picks for 2024
youtube.com • -
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
investorplace.com • -
Alzheimer's Disease Drug Development: Another Lost Year
seekingalpha.com • -
Biogen: LAQEMBI's $10 Billion Potential
seekingalpha.com •